Information about Turkey-TITCK (Türkiye İlaçveTıbbiCihazKurumu)- Approval Processes

Regulatory Authority
Turkish Medicines and Medical Devices Agency (TMMDA)
Link for Regulatory Authorityhttps://www.titck.gov.tr/iletisim
Local AuthorizedYes
ClassificationNovelty, Therapeutic Category, and Risk.
Preparation and DocumentationApplications should be submitted in the corrected application file format, not as attachments.
Corrections in the Electronic Document Management System (EBYS) should also be added in the Common Technical Document (CTD) format.
Official documents issued by a competent authority outside Turkey (place of production) should be included.
Documents (e.g., permit, Good Manufacturing Practices (GMP), CPP documents, license) from other countries must be apostilled or consulate approved.
Information in the license application files (Modules 1 to 5) must be compatible and arranged according to the Guide on File Requirements for Electronic License Applications.
Information about the reference medicinal product, including where it is registered and where it was first used, should be provided.
A second preliminary examination application for incomplete applications must be submitted within 30 days.
Additional applications with documents cannot be included in file modules and are not accepted.
The licensing date, legal status of the product, and packaging size differences must be stated.
The Application Form should include information on containers, lids, application devices, and Summary of Product Characteristics (SPC) or KullanmaTalimatı (KT).
Section 2.6.2: Specify only ‘used in the manufacturing process of the medical product.’
Section 2.3.2: Corrections post should be mentioned.
Compliance with Regulation on Licensing of Medicinal Products for Human Use Article 9, 1-b for hybrid applications.
Maintain a registry of officials who have signed the Contract Manufacturing Agreement, as outlined in Annex 6.22.
Submit a risk management plan for drugs containing a medical device during the registration application.
Certificates of analysis for excipients should be submitted in Module 3.2.P.4.4. If not applicable, select the ‘None’ option, ensuring this information aligns with the application file.
For drugs containing a new active ingredient, biotechnological drugs, biosimilar drugs, and reference drugs, relevant information should be presented.
In Module 3.P.7 Section 2.2.4, complete information related to finished product packaging specifications and certificates of analysis. Attestations must be submitted.
Registration Timeline30 to 60 months
Registration Fee5 Years
Join hundreds of companies who trust OMC Medical for their regulatory needs.